Avails Medical Awarded Additional $1.7m in CARB-x Funding for the Development of Its Rapid Antibiotic Susceptibility Testing Device to Identify the Most Effective Antibiotic Therapy

Avails Medical, a pioneer in rapid, automated, and fully electrical antibiotic susceptibility testing (eAST^™) announced today the transition to the next phase of its CARB-X grant. Avails was awarded an additional $1.7 million in non-dilutive funding from CARB-X, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator. CARB-X is a global non-profit partnership based at Boston University School of Law and dedicated to funding the development of new antibiotics, vaccines, diagnostics and other products to address the rising global threat of antibiotic-resistant bacteria.

Funds will support the accelerated development of the Avails Medical eAST system, a fully electrical antibiotic susceptibility testing device that reduces the time-to-results to an average of five hours. The Avails platform will enable health care providers to more efficiently determine the most effective antibiotic treatment for patients with severe bloodstream infections, particularly those involving multidrug-resistant pathogens.

“We are delighted to support the important work of Avails Medical”, said Erin Duffy, Ph.D., Chief of Research and Development of CARB-X. “The Avails eAST diagnostic platform offers a very practical solution to reducing time to actionable AST results, which is critical in guiding antibiotic therapy decisions, especially in hospital centers that are human-resource constrained.”

“Every hour counts for a patient with sepsis. Avails’ unique rapid eAST technology presents a meaningful opportunity to improve patient care by shortening the time to effective antibiotics at an affordable cost, ” said Eszter Deak, Ph.D., Director of Scientific and Medical Affairs at Avails Medical. “We are honored and pleased that CARB-X continues to recognize the value of Avails Medical’s eAST system and supports us in our endeavor to significantly improve therapy decision support for bloodstream infections,” said Oren Knopfmacher, CEO of Avails Medical.

Avails could be eligible for additional funding from CARB-X upon successful completion of milestones.